Ipamorelin vs Sermorelin: GHRP vs GHRH Growth Hormone Secretagogues Compared
Ipamorelin targets ghrelin receptors with a ~2-hour half-life; sermorelin activates GHRH receptors but clears in ~10-15 minutes. Compare mechanism, selectivity, and FDA status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Ipamorelin vs sermorelin research comparisons come up frequently in growth hormone (GH) axis literature because the two peptides stimulate GH release through entirely different receptor systems while producing an overlapping downstream effect: pulsatile GH secretion from the anterior pituitary. Ipamorelin is a ghrelin receptor agonist; sermorelin is a GHRH receptor agonist. Researchers selecting between the two — or studying them in combination — are choosing between two distinct pharmacological entry points into the same physiological axis.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Ipamorelin selectively activates ghrelin receptors (GHS-R1a) with minimal cortisol or prolactin co-release and an approximate 2-hour half-life, while sermorelin activates GHRH receptors to trigger a more physiologically native GH pulse but is cleared from circulation within 10–15 minutes, a difference in receptor pharmacology and pharmacokinetics that shapes how each is used in published research protocols.
Ipamorelin: mechanism and evidence base
Ipamorelin is a pentapeptide classified as a growth hormone secretagogue (GHS) that functions as a ghrelin-mimetic — it binds ghrelin receptors (growth hormone secretagogue receptors, GHS-R1a) on pituitary somatotroph cells. This binding stimulates GHRH-pathway signaling while suppressing somatostatin tone, amplifying endogenous GH pulsatility rather than replacing it outright.
The foundational characterization of ipamorelin's selectivity comes from Raun et al. (1998), published in the European Journal of Endocrinology, which established that ipamorelin releases GH with efficacy comparable to other GHS-R1a agonists of its era while producing minimal elevation of ACTH or cortisol relative to broader-acting secretagogues (PMID 9849822). This selectivity profile is the primary reason ipamorelin is distinguished in the literature from non-selective GHS compounds such as hexarelin, which co-stimulates cortisol and prolactin alongside GH.
A 2026 critical review of peptide and peptide-analog use in sport and research contexts also references ipamorelin as one of the most widely cited selective GHS-R1a agonists in non-clinical use, while noting that long-term safety data under supraphysiological or combined-protocol dosing remain limited (PMID 41880199).
Sermorelin: mechanism and evidence base
Sermorelin is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone — GHRH(1-29) — that binds GHRH receptors on the same somatotroph cells, activating G-protein-coupled signaling that triggers GH synthesis and release. Because it engages the GHRH receptor directly rather than the ghrelin receptor, sermorelin is often described in the literature as reproducing a more "physiologic" upstream signal, since it works through the same receptor endogenous GHRH uses.
Sermorelin has a notable regulatory history among GHRH analogues: it received FDA approval under the brand name Geref for pediatric GH-deficiency diagnosis and treatment before the manufacturer voluntarily withdrew the product from the US market in 2008 for commercial reasons unrelated to safety. That approval-and-withdrawal history means published sermorelin data include a comparatively well-characterized clinical pharmacokinetic and safety dataset from its Geref-era trials, even though no FDA-approved sermorelin product currently exists.
Published dose-response data describe peak GH concentrations reaching 2–4 times baseline within 15–60 minutes of controlled administration in clinical trial settings, with a circulating half-life on the order of 10–15 minutes — among the shortest of the GHRH-class analogues studied (PMID 41880199).
Neither peptide is a direct substitute for exogenous recombinant human growth hormone (rhGH) in research design. Because both work upstream — stimulating the pituitary rather than supplying GH directly — published protocols using either compound generally preserve at least some of the endogenous negative-feedback regulation on the GH–IGF-1 axis, a distinction researchers frequently cite when designing comparative pharmacodynamic studies against direct rhGH administration.
Side-by-side comparison
| Ipamorelin | Sermorelin | |
|---|---|---|
| Receptor target | Ghrelin receptor (GHS-R1a) | GHRH receptor (GHRH-R) |
| Peptide class | Pentapeptide GHS | 29-amino-acid GHRH(1-29) analogue |
| Reported half-life | ~2 hours | ~10–15 minutes |
| Cortisol/prolactin co-release | Minimal, per selectivity data | Not a primary mechanism concern (GHRH pathway) |
| FDA approval status | Never FDA-approved; investigational | Previously FDA-approved (Geref), withdrawn 2008 |
| Primary research use | Selective GHS-R1a pharmacology, doping-detection research | GHRH-receptor pharmacodynamics, historical GHD stimulation testing |
Differential research applications
Because ipamorelin and sermorelin engage different receptors, published protocols frequently pair them rather than treat them as substitutes — a combined GHRH-receptor-plus-ghrelin-receptor approach is intended to produce additive GH release relative to either agonist alone, a rationale explored further in coverage of CJC-1295, a longer-acting GHRH analogue often studied alongside ipamorelin. Researchers modeling dosing intervals and clearance for either compound, or for GHRH/GHS combination protocols, commonly reference pharmacokinetic half-life data side by side; the site's half-life reference tool compiles reported elimination half-lives across GH-axis peptides for this purpose.
Where a study needs a receptor-selective probe with reduced ACTH/cortisol confound, ipamorelin's selectivity data make it the more common choice in mechanistic pituitary-axis research. Where a study is specifically characterizing GHRH-receptor pharmacodynamics — or drawing on the deeper historical clinical trial base — sermorelin's Geref-era dataset remains a frequently cited reference point, despite its short half-life complicating sustained-exposure study designs.
Sermorelin's short half-life also has methodological consequences for pulsatility research. Because native GH secretion is itself pulsatile — with discrete secretory bursts separated by low-trough intervals — a rapidly cleared secretagogue like sermorelin is sometimes considered mechanistically closer to reproducing that native pulse pattern than a longer-acting agonist would. Ipamorelin's roughly 2-hour half-life, by contrast, sustains receptor engagement over a longer window, which published protocols have used to characterize the shape and duration of a single ghrelin-receptor-driven secretory episode rather than to mimic multiple discrete native pulses. Researchers designing sampling schedules for GH stimulation testing generally treat this pharmacokinetic contrast as a primary variable when selecting blood-draw intervals and study duration.
Regulatory and compounding status
Ipamorelin has never held FDA approval for any indication and is treated in the literature as an investigational research compound; its 503A compounding status has been the subject of ongoing FDA Pharmacy Compounding Advisory Committee (PCAC) review alongside other growth hormone secretagogues. Sermorelin's regulatory position is more layered: it carries prior FDA approval history (Geref, withdrawn 2008) but no currently active approval, and is available in the US primarily through 503A compounding pharmacies pending further PCAC evaluation. Neither peptide is currently a component of an FDA-approved product for adult use, and both are prohibited by the World Anti-Doping Agency (WADA) as GH-axis secretagogues, with sermorelin's structural homology to endogenous GHRH and ipamorelin's short-lived circulating profile both cited as complicating factors for anti-doping detection assays.
Cited studies
- PMID 9849822 — Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998. https://doi.org/10.1530/eje.0.1390552
- PMID 41880199 — "A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review." 2026.
- PMID 16352683 — Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 2006. https://doi.org/10.1210/jc.2005-1536
Frequently asked questions
Q: What is the main difference between ipamorelin and sermorelin?
A: Ipamorelin is a ghrelin receptor (GHS-R1a) agonist, while sermorelin is a GHRH receptor agonist. Both ultimately stimulate pituitary GH release, but through different upstream receptor systems, which gives them different selectivity profiles and half-lives in published research.
Q: Which has a longer half-life, ipamorelin or sermorelin?
A: Ipamorelin's reported circulating half-life of approximately 2 hours is substantially longer than sermorelin's, which is cleared within roughly 10–15 minutes. This difference is one of the most cited pharmacokinetic distinctions between the two compounds in GH-axis research.
Q: Is sermorelin FDA approved?
A: Sermorelin previously held FDA approval under the brand name Geref for pediatric growth hormone deficiency diagnosis and treatment, but the manufacturer voluntarily withdrew it from the US market in 2008 for commercial reasons. No FDA-approved sermorelin product currently exists.
Q: Do researchers study ipamorelin and sermorelin together?
A: Yes. Because they act on different receptors — ghrelin receptor versus GHRH receptor — combination protocols pairing a GHS-R1a agonist like ipamorelin with a GHRH-pathway analogue are a recurring theme in published GH-axis research, on the rationale that the two mechanisms produce additive rather than redundant GH release.
Q: Why does ipamorelin cause less cortisol elevation than other GHRPs?
A: Raun et al. (1998) reported that ipamorelin's receptor-binding profile produces GH release with substantially less co-stimulation of ACTH and cortisol than earlier, less-selective growth hormone-releasing peptides, a selectivity attributed to its specific binding characteristics at GHS-R1a relative to compounds like hexarelin.
See also:
- CJC-1295 vs Sermorelin: GHRH Analogue Research Comparison — compares sermorelin against a longer-acting GHRH analogue.
- MK-677 vs Ipamorelin: Oral Ghrelin Mimetic vs Injectable GHRP — contrasts ipamorelin with an orally active ghrelin receptor agonist.
- Is Sermorelin FDA Approved? Regulatory History and Current Status — full detail on the Geref approval and 2008 withdrawal.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.